The Essential Resource for the Medical Design Engineering Community
Subscribe to MDT Magazine All

Epoxy Combines High Strength and Toughness With Chemical and Abrasion Resistance

September 8, 2010 6:33 am | Master Bond, Inc. | Product Releases | Comments

Combining the benefits of epoxy resins and polyurethanes, Master Bond Polymer System EP30D-7 offers superior strength, flexibility, abrasion resistance, and toughness.

Misonix Announces New Distribution Agreement for France

September 8, 2010 6:32 am | by Bio-Medicine.Org | News | Comments

FARMINGDALE, N.Y., Sept. 8 /- Misonix, Inc. (Nasdaq: MSON ), a developer of state of the art, ultrasonic medical device technology, which worldwide is used for acute health conditions, has entered into a new, three year, exclusive distribution agreement with Cormedica s.a.s.  Based...


Updated Phase 2 Data With Flutemetamol Published in Annals of Neurology

September 8, 2010 6:31 am | by Bio-Medicine.Org | News | Comments

PRINCETON, N.J., Sept. 7 /- GE Healthcare announced today that results from its multicenter phase 2 study of flutemetamol were published in the September issue of Annals of Neurology . Flutemetamol is an investigational positron emission tomography (PET) imaging agent being developed by...


Circuit Protection Features Broad Range of Trigger Currents

September 8, 2010 6:24 am | Product Releases | Comments

Bourns Inc., a leading manufacturer and supplier of electronic components, offers the company’s next-generation transient blocking unit (TBU) series of circuit protection devices...

Researchers Explore Use for Head, Neck, Prostate, Breast and Lung Tumors, as Well as More Complex Blood Cancer and Mesothelioma Treatments

September 8, 2010 5:45 am | by The Associated Press | News | Comments

TomoTherapy Incorporated (NASDAQ: TOMO), maker of advanced radiation therapy solutions for cancer care, today announced that 82 studies examining the use of the TomoTherapy@ treatment system to treat common, complex and rare tumors...

electronica 2010 ? electronics industry demonstrates its future viability

September 8, 2010 5:33 am | by I-Micronews | News | Comments

electronica will present the future of the electronics industry at the New Munich Trade Fair Center from November 9 to 12, 2010.

Cardiorobotics collects $500K of planned $5M round

September 8, 2010 5:33 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Less than one year after raising a $5 million funding round, Cardiorobotics Inc. has started another $5 million round with a $500,000 tranche.

Diabetes-focused biotech Rhythm closes $40M Series A round

September 8, 2010 5:32 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Rhythm Pharmaceuticals Inc., a startup focused on obesity and diabetes treatments, had closed a $40 million Series A financing, funded by MPM Capital and Third Rock Ventures, both of Boston, as well as New Enterprise Associates of Maryland.


Streamline Health Document Workflow Solutions Purchased By Tampa, Florida-Based Hospital

September 8, 2010 3:33 am | by Bio-Medicine.Org | News | Comments

CINCINNATI, Sept. 8 /- Streamline Health Solutions, Inc. (Nasdaq: STRM ) a leading provider of document workflow solutions for hospitals, today announced that a leading Tampa, Florida-based medical institution has purchased three additional workflow licenses to expand the use of...


STAAR Surgical Launches New Visian ICL™ Product Line Extensions at ESCRS

September 8, 2010 3:33 am | by Bio-Medicine.Org | News | Comments

MONROVIA, Calif., Sept. 8 /- STAAR Surgical Company (Nasdaq: STAA ), the leading worldwide developer, manufacturer and marketer of phakic intraocular lenses, today announced that the Visian Implantable Collamer® Lens (ICL) was featured prominently in more than 40 presentations by...


MAP Pharmaceuticals Announces All Non-Asthmatic Patients Complete Treatment in Open-Label Trial and Completion of Treatment in QT Trial for LEVADEX™ Clinical Program

September 8, 2010 3:33 am | by Bio-Medicine.Org | News | Comments

MOUNTAIN VIEW, Calif., Sept. 8 /- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ) today announced that all non-asthmatic patients and a subset of asthmatic patients have completed 12 months of treatment in the open-label safety trial of LEVADEX™. In addition, the Company has completed...


Isis Pharmaceuticals to Present at the Stifel Nicolaus 2010 Healthcare Conference

September 8, 2010 3:33 am | by Bio-Medicine.Org | News | Comments

CARLSBAD, Calif., Sept. 8 /- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ), the leader in antisense therapeutics, today announced that management will present a company overview at Stifel Nicolaus' 2010 Healthcare Conference on Thursday, September 16, 2010 at 8:35 a.m. ET at The Four Seasons...


MAP Pharmaceuticals Reports No Difference in Pulmonary Artery Pressure Between LEVADEX™ and Placebo in Pharmacodynamics Trial

September 8, 2010 3:33 am | by Bio-Medicine.Org | News | Comments

MOUNTAIN VIEW, Calif., Sept. 8 /- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ) today reported results from a pharmacodynamics (PD) trial comparing the acute effects on pulmonary artery pressure of LEVADEX™, dihydroergotamine mesylate (DHE) administered intravenously (IV) and placebo....


N30 Pharma Initiates Phase 1 Trials of Novel Reductase Inhibitor

September 8, 2010 3:33 am | by Bio-Medicine.Org | News | Comments

BOULDER, Colo., Sept. 8 /- N30 Pharmaceuticals, LLC today announced it has dosed the first human subject with N6022, a first-in-class inhibitor of s-nitrosoglutathione reductase (GSNOR). N6022 is the first GSNOR inhibitor to be administered to human beings. N6022 has the potential to be...


Cardiogenesis Executive Chairman Paul J. McCormick Updates Commercial and Regulatory Progress in Interview With Wall Street Reporter, Available Online

September 8, 2010 3:32 am | by Bio-Medicine.Org | News | Comments

IRVINE, Calif., Sept. 8 /- Cardiogenesis Corporation (OTCQB: CGCP) today announced that the Wall Street Reporter has interviewed Cardiogenesis' Executive Chairman Paul J. McCormick.  The interview includes a discussion of the Company's results for the first half of 2010, including an...



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.